123 related articles for article (PubMed ID: 37160663)
1. Injection Site Reactions Before and After Intramuscular Injection Technique Revision: A Postmarketing Analysis of NALDEBAIN® From 2017 to 2022.
Man KM; Lee SO; Lu CH; Wong CS; Sun WZ
Asian J Anesthesiol; 2023 Mar; 61(1):14-20. PubMed ID: 37160663
[TBL] [Abstract][Full Text] [Related]
2. Severe injection site reactions after subcutaneous administration of Sayana©.
Jödicke AM; Dahmke H; Damke B; Schäublin M; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2017; 147():w14432. PubMed ID: 28634970
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
[TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
5. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
[TBL] [Abstract][Full Text] [Related]
6. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
[TBL] [Abstract][Full Text] [Related]
7. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reactions to anthroposophic and homeopathic solutions for injection: a systematic evaluation of German pharmacovigilance databases.
Jong MC; Jong MU; Baars EW
Pharmacoepidemiol Drug Saf; 2012 Dec; 21(12):1295-301. PubMed ID: 22692862
[TBL] [Abstract][Full Text] [Related]
9. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
10. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
[TBL] [Abstract][Full Text] [Related]
11. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.
Aldea A; García Sánchez-Colomer M; Fernández Quintana E; García Sáiz M
Eur J Clin Pharmacol; 2012 Sep; 68(9):1329-38. PubMed ID: 22415248
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
[TBL] [Abstract][Full Text] [Related]
14. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
Bhushan S; Ray RS; Prakash J; Singh GN
Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
16. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
Stottlemyer BA; McDermott MC; Minogue MR; Gray MP; Boyce RD; Kane-Gill SL
Ther Adv Drug Saf; 2023; 14():20420986231181334. PubMed ID: 37332887
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy.
Leporini C; De Sarro C; Palleria C; Caccavo I; Piro B; Citraro R; De Sarro G
Drug Saf; 2022 Nov; 45(11):1381-1402. PubMed ID: 36112324
[TBL] [Abstract][Full Text] [Related]
18. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden.
Holm L; Ekman E; Jorsäter Blomgren K
Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):335-343. PubMed ID: 28071845
[TBL] [Abstract][Full Text] [Related]
19. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
